Regular use of aspirin and other non-steroidal anti-inflammatory drugs and breast cancer risk for women at familial or genetic risk: a cohort study

[1]  Elsdon Storey,et al.  Effect of Aspirin on All‐Cause Mortality in the Healthy Elderly , 2018, The New England journal of medicine.

[2]  E. Winer,et al.  ABC trial (A011502): A randomized phase III double-blinded placebo-controlled trial of aspirin as adjuvant therapy breast cancer. , 2018 .

[3]  B. Bonanni,et al.  A Survey among Breast Cancer Specialists on the Low Uptake of Therapeutic Prevention with Tamoxifen or Raloxifene , 2017, Cancer Prevention Research.

[4]  J. Kirk,et al.  Motivators and barriers of tamoxifen use as risk-reducing medication amongst women at increased breast cancer risk: a systematic literature review , 2017, Hereditary Cancer in Clinical Practice.

[5]  W. Chung,et al.  Risks of Breast, Ovarian, and Contralateral Breast Cancer for BRCA1 and BRCA2 Mutation Carriers , 2017, JAMA.

[6]  Liming Lu,et al.  Aspirin as a potential modality for the chemoprevention of breast cancer: A dose-response meta-analysis of cohort studies from 857,831 participants , 2017, Oncotarget.

[7]  J. Cuzick,et al.  Prescribing tamoxifen in primary care for the prevention of breast cancer: a national online survey of GPs’ attitudes , 2017, The British journal of general practice : the journal of the Royal College of General Practitioners.

[8]  D. Cameron,et al.  ADD-ASPIRIN: A phase III, double-blind, placebo controlled, randomised trial assessing the effects of aspirin on disease recurrence and survival after primary therapy in common non-metastatic solid tumours , 2016, Contemporary clinical trials.

[9]  Kirsten Bibbins-Domingo,et al.  Aspirin Use for the Primary Prevention of Cardiovascular Disease and Colorectal Cancer: U.S. Preventive Services Task Force Recommendation Statement. , 2016, Annals of internal medicine.

[10]  L. Hartmann,et al.  The Role of Risk-Reducing Surgery in Hereditary Breast and Ovarian Cancer. , 2016, The New England journal of medicine.

[11]  Jack A. Taylor,et al.  Lifetime use of nonsteroidal anti-inflammatory drugs and breast cancer risk: results from a prospective study of women with a sister with breast cancer , 2015, BMC Cancer.

[12]  J. Wardle,et al.  Factors affecting uptake and adherence to breast cancer chemoprevention: a systematic review and meta-analysis , 2015, Annals of oncology : official journal of the European Society for Medical Oncology.

[13]  S. Zhong,et al.  Aspirin Use and Risk of Breast Cancer: Systematic Review and Meta-analysis of Observational Studies , 2015, Cancer Epidemiology, Biomarkers & Prevention.

[14]  A. Whittemore,et al.  Cohort Profile: The Breast Cancer Prospective Family Study Cohort (ProF-SC) , 2015, International journal of epidemiology.

[15]  R. Altman,et al.  PharmGKB summary: ibuprofen pathways , 2015, Pharmacogenetics and genomics.

[16]  J. Llorca,et al.  Effect of COX-2 inhibitors and other non-steroidal inflammatory drugs on breast cancer risk: a meta-analysis , 2015, Breast Cancer Research and Treatment.

[17]  J. Cuzick,et al.  Anastrozole for prevention of breast cancer in high-risk postmenopausal women (IBIS-II): an international, double-blind, randomised placebo-controlled trial , 2014, The Lancet.

[18]  B. Rigas,et al.  Phospho-aspirin (MDC-22) inhibits breast cancer in preclinical animal models: an effect mediated by EGFR inhibition, p53 acetylation and oxidative stress , 2014, BMC Cancer.

[19]  A. Freedman,et al.  Trends in the use of aspirin and nonsteroidal anti‐inflammatory drugs in the general U.S. population , 2014, Pharmacoepidemiology and drug safety.

[20]  H. Yoon,et al.  Aspirin-induced Bcl-2 translocation and its phosphorylation in the nucleus trigger apoptosis in breast cancer cells , 2013, Experimental & Molecular Medicine.

[21]  G. Giles,et al.  Prospective validation of the breast cancer risk prediction model BOADICEA and a batch-mode version BOADICEACentre , 2013, British Journal of Cancer.

[22]  A. LaCroix,et al.  Selective oestrogen receptor modulators in prevention of breast cancer: an updated meta-analysis of individual participant data , 2013, The Lancet.

[23]  Reiko Nishihara,et al.  Aspirin use, tumor PIK3CA mutation, and colorectal-cancer survival. , 2012, The New England journal of medicine.

[24]  Karen A Gelmon,et al.  Exemestane for breast-cancer prevention in postmenopausal women. , 2011, The New England journal of medicine.

[25]  J. Hopper.  Disease-specific prospective family study cohorts enriched for familial risk , 2011, Epidemiologic perspectives & innovations : EP+I.

[26]  J. Abramson.  WINPEPI updated: computer programs for epidemiologists, and their teaching potential , 2011, Epidemiologic perspectives & innovations : EP+I.

[27]  J. Cerhan,et al.  Effect of aspirin and other NSAIDs on postmenopausal breast cancer incidence by hormone receptor status: results from a prospective cohort study , 2011, Breast Cancer Research and Treatment.

[28]  A. Algra,et al.  Long-term effect of aspirin on colorectal cancer incidence and mortality: 20-year follow-up of five randomised trials , 2010, The Lancet.

[29]  S. Kjaer,et al.  Factors associated with a continuous regular analgesic use—a population‐based study of more than 45 000 Danish women and men 18–45 years of age , 2010, Pharmacoepidemiology and drug safety.

[30]  A. Whittemore,et al.  BRCA1 and BRCA2 mutation carriers in the Breast Cancer Family Registry: an open resource for collaborative research , 2009, Breast Cancer Research and Treatment.

[31]  J. Hopper,et al.  Australian clinicians and chemoprevention for women at high familial risk for breast cancer , 2008, Hereditary cancer in clinical practice.

[32]  Jan Lubinski,et al.  International variation in rates of uptake of preventive options in BRCA1 and BRCA2 mutation carriers , 2008, International journal of cancer.

[33]  Gretchen L. Gierach,et al.  Nonsteroidal anti-inflammatory drugs and breast cancer risk in the National Institutes of Health–AARP Diet and Health Study , 2008, Breast Cancer Research.

[34]  H A Risch,et al.  The BOADICEA model of genetic susceptibility to breast and ovarian cancers: updates and extensions , 2008, British Journal of Cancer.

[35]  Serena Landini,et al.  Suppression of aromatase in human breast cells by a cyclooxygenase-2 inhibitor and its analog involves multiple mechanisms independent of cyclooxygenase-2 inhibition , 2008, Steroids.

[36]  D. Moher,et al.  Nonsteroidal Anti-inflammatory Drugs and Cyclooxygenase-2 Inhibitors for Primary Prevention of Colorectal Cancer: A Systematic Review Prepared for the U.S. Preventive Services Task Force , 2007, Annals of Internal Medicine.

[37]  K. Helzlsouer,et al.  Nonsteroidal antiinflammatory drugs, cyclooxygenase polymorphisms, and the risk of developing breast carcinoma among women with benign breast disease , 2006, Cancer.

[38]  John L Hopper,et al.  Analysis of cancer risk and BRCA1 and BRCA2 mutation prevalence in the kConFab familial breast cancer resource , 2006, Breast Cancer Research.

[39]  J. Manson,et al.  Low-dose aspirin in the primary prevention of cancer: the Women's Health Study: a randomized controlled trial. , 2005, JAMA.

[40]  J. Chang-Claude,et al.  A weighted cohort approach for analysing factors modifying disease risks in carriers of high‐risk susceptibility genes , 2005, Genetic epidemiology.

[41]  D. Stram,et al.  Nonsteroidal anti-inflammatory drug use and breast cancer risk by stage and hormone receptor status. , 2005, Journal of the National Cancer Institute.

[42]  R. Hirsch,et al.  Frequent monthly use of selected non‐prescription and prescription non‐narcotic analgesics among U.S. adults , 2005, Pharmacoepidemiology and drug safety.

[43]  Robert Riddell,et al.  Cardiovascular events associated with rofecoxib in a colorectal adenoma chemoprevention trial. , 2005, The New England journal of medicine.

[44]  D. Easton,et al.  The BOADICEA model of genetic susceptibility to breast and ovarian cancer , 2004, British Journal of Cancer.

[45]  Norman Boyd,et al.  The Breast Cancer Family Registry: an infrastructure for cooperative multinational, interdisciplinary and translational studies of the genetic epidemiology of breast cancer , 2004, Breast Cancer Research.

[46]  Stuart J Pocock,et al.  Soya food intake and risk of endometrial cancer among Chinese women in Shanghai: population based case-control study , 2004, BMJ : British Medical Journal.

[47]  R. Goldbohm,et al.  Familial breast cancer: collaborative reanalysis of individual data from 52 epidemiological studies including 58 209 women with breast cancer and 101 986 women without the disease , 2001, The Lancet.

[48]  P. Ghahramani,et al.  Aspirin for primary prevention of coronary heart disease: safety and absolute benefit related to coronary risk derived from meta-analysis of randomised trials , 2001, Heart.

[49]  R Day,et al.  Comparison of upper gastrointestinal toxicity of rofecoxib and naproxen in patients with rheumatoid arthritis. VIGOR Study Group. , 2000, The New England journal of medicine.

[50]  Y. Loke,et al.  Risk of gastrointestinal haemorrhage with long term use of aspirin: meta-analysis , 2000, BMJ : British Medical Journal.

[51]  T. Żebro,et al.  PROSTAGLANDINS AND BREAST CANCER , 1977, The Lancet.

[52]  J. Cerhan,et al.  Personalizing Aspirin Use for Targeted Breast Cancer Chemoprevention in Postmenopausal Women. , 2016, Mayo Clinic proceedings.

[53]  T. Luo,et al.  Aspirin use and breast cancer risk: a meta-analysis , 2011, Breast Cancer Research and Treatment.

[54]  Tx Station.  Stata Statistical Software: Release 7. , 2001 .

[55]  disease: safety and absolute benefit related to coronary risk derived from meta-analysis of randomised trials , 2022 .